Status:
COMPLETED
Proteomics to Identify Prognostic Markers After CPR and to Estimate Neurological Outcome
Lead Sponsor:
Universitätsklinikum Köln
Conditions:
Cardiac Arrest
Eligibility:
All Genders
18+ years
Brief Summary
Proteomics is used to identify prognostic markers after CPR. Additionally neurological outcome should be estimated by specific protein alterations and affections of pathways.
Detailed Description
Proteomics is used to identify prognostic markers after CPR, i.e. altered proteins on a 2G-gel. Additionally neurological outcome should be estimated by specific protein alterations and affections of ...
Eligibility Criteria
Inclusion
- cardiac arrest
Exclusion
- trauma
Key Trial Info
Start Date :
September 1 2014
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
November 1 2020
Estimated Enrollment :
20 Patients enrolled
Trial Details
Trial ID
NCT02247947
Start Date
September 1 2014
End Date
November 1 2020
Last Update
November 4 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University Hospital of Cologne
Cologne, North Rhine-Westphalia, Germany, 50937